PUBLICATION OF REGISTRATION DOCUMENT AND SECURITIES NOTE

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PUBLICATION OF REGISTRATION DOCUMENT AND SECURITIES NOTE

Espoo, Finland, 2013-09-26 14:15 CEST (GLOBE NEWSWIRE) -- EFORE PLC    Stock Exchange Release                       26 September 2013     at 3.15 p.m. Efore Plc (“Efore” or “Company”) will publish a registration document and securities note (together “Offer and Listing Prospectus”) approved by the Finnish Financial Supervisory Authority regarding the share issue that was decided today on 26 September 2013 by the Board of Directors (the “Share Issue”). The Offer and Listing Prospectus also pertain to the application for public listing of shares issued to the sellers of Roal Electronics S.p.A as a part of the payment of the purchase price. The Offer and Listing Prospectus is available electronically as of 27 September 2013 at 12 a.m., at the latest, on the Company’s website www.efore.com/shareissue2013 and at the subscription place, Alexander Corporate Finance Oy, www.acf.fi . The Offer and Listing Prospectus will also be available in paper form at the subscription place in Alexander Corporate Finance Oy and in the Company. The Offer and Listing Prospectus will be available only in Finnish. Efore announced on 12 July 2013 that a directed share issue was entered in the Finnish Trade Register in addition to announcing on 26 August 2013 that it is preparing to issue new shares for subscription. The registration document contains the following previously unpublished information: The following pro forma information concerning the Roal transaction was prepared based on the requirements set in Schedule II of the Commission’s Prospectus Regulation. The non-audited pro forma based financial information described below is intended for illustrative purposes only, and due to their nature, they describe a hypothetical situation and not the actual financial position or financial result of Efore. Efore Plc signed an agreement 10 July 2013 to acquire the entire share capital of Italian-based Roal Electronics S.p.A (Roal). The transaction was closed on 11 July 2013. The purchase price was EUR 9.7 million. 60 per cent of the purchase price was paid in cash and 40 per cent in Efore shares. The Purchase price paid in Efore shares amounted to 5,243,243 Efore shares. Efore’s Board of Directors decided to use the authorisation granted by the AGM to assign the shares to the sellers. The shares were valued at EUR 0.74 per share. The subscribing sellers agreed to refrain from selling their Efore shares for a period of twelve (12) months from the closing date of the transaction. In Efore’s interim report dated 31 July 2013, which is referred to in the registration document, Roal was consolidated into the Efore Group. The acquisition cost calculation concerning the consolidation was presented in its preliminary form in the interim report dated 31 July 2013. The balance sheet information provided in the interim report dated 31 July 2013 therefore already illustrates the balance sheet effect that the consolidation of the Roal Group has had on the Efore Group. The information presented below pertaining to the effects the consolidation of the Roal Group could have had on the 12-month 2012 profit and loss sheet and the 6-month 2013 profit and loss sheet is presented only for illustrative purposes. The pro forma information illustrates the possible profit and loss sheets of the Efore Group and the Roal Group for a 12-month period in 2012 and a 6-month period in 2013 if the Roal Group had been consolidated into the Efore Group on 11 November 2011. The pro forma profit and loss information is based on the Efore Group’s audited IFRS financial statement for the financial period of 1 November 2011 to 31 October 2012 and Roal Electronics S.p.A’s non-audited IFRS adjusted financial statement for the financial period of 1 January 2012 to 31 December 2012 as well as the Efore Group’s non-audited six-month IFRS interim report for the period of 1 November 2012 to 30 April 2013 and Roal Electronics S.p.A’s non-audited IFRS adjusted six-month interim accounts for the time period of 1 January to 30 June 2013. Historical information pertaining to Roal Electronics S.p.A was compiled in accordance with local legislation (IT GAAP). A separate table shows how Roal Electronics S.p.A’s historical financial information from the financial period of 1 January to 31 December 2012 and for the period of 1 January to 30 June 2013 were adjusted to abide by the IFRS standards applied by the Efore Group. The profit and loss account for the financial period of 1 January 2012 to 31 December 2012 compiled in accordance with the IT GAAP has been audited, while the profit and loss account for the period of 1 January 2013 to 30 June 2013 has not been audited. The IRFS transfer date applied to the adjustment is 1 January 2012.

             
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME        
             
    Audited Non-audited      
EUR million   1 Oct 2011 to 1 Jan 2012 to      
    31 Oct 2012 31 Dec 2012 Pro forma adjust-ments Ref. Group
    12 mo IFRS 12 mo IFRS      
    EFORE ROAL      
NET SALES 78.1 39.6     117.7
             
Change in inventories of        
finished goods and work in progress 2.3 -0.8 -0.4 1 1.1
Other operating income 0.6 1.4     2.0
Materials and services -55.9 -30.8     -86.7
Employee benefits expenses -15.9 -7.0     -22.9
Depreciation   -3.0 -1.5 -0.3 2 -4.7
Other operating expenses -8.8 -0.4 -1.0 3 -10.2
RESULTS FROM OPERATING ACTIVITIES -2.6 0.5     -3.8
Financing income 1.7 0.1     1.7
Financing expenses -2.1 -0.5 -0.1 4 -2.7
RESULT BEFORE TAX -3.0 0.1     -4.7
Tax on income from operations   0.7 0.0 0.2 5 0.9
RESULT FOR THE PERIOD -2.3 0.1                  -1.5   -3.8
OTHER COMPREHENSIVE INCOME Audited 1 Oct 2011 to 31 Oct 2012, 12 mo, IFRS EFORE Non-audited 1 Jan 2012  to 31 Dec 2012, 12 mo, IFRS ROAL Pro-forma adjust-ments   Group
Items that may be reclassified subsequently to profit or loss            
Translation differences   1,4 0,0     1,4
Total comprehensive income   -0,9 0,1 -1,5   -2,4
             
NET PROFIT/LOSS ATTRIBUTABLE            
             
To equity holders of the parent   -2,3 0,1 -1,5   -1,5
To non-controlling interest   -0,1 0,0     -0,1
             
TOTAL COMPREHENSIVE INCOME          
ATTRIBUTABLE TO:            
Equity holders of the parent   -0,9 0,1 -1,5   -2,4
Non-controlling interest   -0,1 0,0     -0,1
  Non-audited Non-audited      
EUR million 1 Nov 2012 to   1 Jan 2013 to      
  30 Apr 2013 30 Jun 2013 Pro forma  adjustments Ref. Group
  6 mo IFRS 6 mo IFRS      
  EFORE ROAL      
NET SALES 28.6 19.2     47.7
           
Change in inventories of          
finished goods and work in progress                                 0.8 0.6     1.4
Other operating income 0.1 0.2     0.3
Materials and services -21.0 -15.0     -36.0
Employee benefits expenses -7.2 -4.0     -11.2
Depreciation -1.1 -0.8 -0.1 2 -2.0
Other operating expenses -3.6 -0.2 0.5 3 -3.3
RESULTS FROM OPERATING ACTIVITIES -3.4 -0.1     -3.1
Financing income 0.6 0.1     0.7
Financing expenses -0.7 -0.2 0.0 4 -0.9
RESULT BEFORE TAX -3.5 -0.2                   -3.4
Tax on income from operations 0.1 -0.1 0.0 5 0.1
RESULT FOR THE PERIOD -3.4 -0.3                  0.4   -3.3
           
OTHER COMPREHENSIVE INCOME  Non-audited  1 Nov 2012 to 30 Apr 2013, 6 mo, IFRS EFORE  Non-audited  1 Jan 2013  to 30 Jun 2013, 6 mo, IFRS ROAL  Proforma adjustments    Group
Items that may be reclassified subsequently to profit or loss          
Translation differences 0,0 -0,1     -0,1
Total comprehensive income -3,3 -0,4 0,4   -3,4
           
NET PROFIT/LOSS ATTRIBUTABLE          
           
To equity holders of the parent -3,3 -0,3 0,4   -3,3
To non-controlling interest 0,0 0,0     0,0
           
TOTAL COMPREHENSIVE INCOME          
ATTRIBUTABLE TO:          
Equity holders of the parent -3,3 -0,4 0,4   -3,4
Non-controlling interest 0,0 0,0     0,0

Referral information: Descriptions of the pro forma adjustments made to the non-audited pro forma profit and loss accounts: 1: Dismantlement of the allocation of the current assets’ fair value. The stock of consumer-ready products acquired in connection with the merging of the operations was recorded separately from the business value and measured at its fair value. Altogether EUR 0.4 million was added to the book value of the acquired stock of consumer-ready products. The stock of customer-ready products now measured at its fair value is expected to be written off in its entirety during the first year and thereby the adjustment of the change in stock is EUR 0.4 million in the pro forma profit and loss accounts vis-à-vis the 12-month profit and loss account for the year 2012. 2: The write-off of the allocation of the fair value of the intangible fixed assets and the piece of real estate. The intangible fixed assets and the piece of real estate acquired in connection with the merging of the operations were recorded separately from the business value at the fair value thereof at the time of acquisition. Altogether EUR 2.0 million was preliminary directed to immaterial rights, i.e. primarily clientele and product rights, in the acquisition. The write-off period of such goods has preliminarily been set at seven (7) years. The fair value of the piece of real estate located in Italy is EUR 0.9 million lower than its book value. The remaining write-off period for the piece of real estate is twenty (20) years. The pro forma adjustments made to related write-offs total altogether EUR 0.26 million vis-à-vis the profit and loss account for the 12-month time period in 2012 and EUR 0.13 million vis-à-vis the profit and loss account for the six-month period in 2013. 3: The transaction costs of the acquisition. The Group estimates that altogether EUR 1.0 million will be incurred in expert fees in connection with the transaction. The transactions are in their entirety included in the 12-month profit and loss account for 2012. As EUR 0.5 million of the transaction costs were, in reality, incurred during a six-month period in 2013, these realised costs were retracted as a pro forma adjustment from the other operating expenses set out in the six-month profit and loss account for 2013. The adjustment has a one-off effect on the issuer of the shares. 4: Costs incurred for the financing loan acquired for the purposes of the acquisition. The acquisition was partially funded through a EUR 2.0 million third-party loan. The loan period is five (5) yeas and the interest is 3.9 per cent. As a pro forma adjustment, the interest costs incurred during the twelve-month period in 2012 will increase by EUR 0.08 million and the interest costs incurred during the six-month period in 2013 will increase by EUR 0.04 million. The adjustment has a continuous effect on the issuer of the shares. 5: The tax consequences of the adjustments. The ameliorating effect of the deferred tax related to the pro forma adjustments set out above in sections 1 and 2 is EUR 0.2 million for the twelve-month profit and loss account for 2012 and EUR 0.05 million for the six-month profit and loss account for 2013. Sections 3 and 4 do not involve a deferred tax claim as the parent company has earlier significant un-used tax losses whose deferred tax claims have not been recorded. An appendix to the calculation presented in the registration document portrays how Roal Electronics S.p.A’s IFRS adjusted result for the financial period of 1 January to 31 December 2012 was derived from Roal Electronics S.p.A’s audited result for the financial period of 1 January 2012 to 31 December 2012 that abided by local legislation (IT GAAP) as well as how Roal Electronics S.p.A’s IRFS adjusted six-month result for the time period of 1 January to 30 June 2013 was derived from Roal Electronics S.p.A’s non-audited six-month result for the time period of 1 January 2013 to 30 June 2013 that abided by local legislation (IT GAAP). EFORE PLC Board of Directors For further information, please contact Mr Vesa Vähämöttönen, CEO, tel. +358 9 4784 6312. DISTRIBUTION NASDAQ OMX Helsinki Oy Principal media Efore Group The Efore Group is an international company that develops and produces demanding power products. Efore's head office is based in Finland, and its production units are located in China and Tunisia. Sales and marketing operations are located in Europe, the United States and China. In the fiscal year ending in October 2012, consolidated net sales totalled EUR 78.1 million, and the Group's personnel averaged 888. The company's shares are quoted on Nasdaq OMX Helsinki Oy. www.efore.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 7

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 3

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 4

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 2

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Season Highlights: Constellation, Delta, and Walgreens

Updated Category News Views 182

Earnings Season Highlights: Key Companies Preparing to Report The financial markets are buzzing as earnings season continues. This is an exciting time for investors and analysts alike as companies unveil their financial performance. On the horizon are a few major players that are set to announce their earnings. Notably, Constellation Brands (NYSE: STZ), Delta Air Lines...

Continue Reading
Mitek Plans Conference Call for Fiscal First Quarter Results

Updated Category News Views 98

Mitek Plans Conference Call for Fiscal First Quarter Results Mitek Systems, Inc. (NASDAQ: MITK), a leading player in digital identity verification and mobile capture technologies, is set to announce its financial results for the first quarter of the fiscal year. The financial information will be publicly released on an upcoming Monday, shortly before a conference call...

Continue Reading
ABN AMRO and Blackstone Forge Strategic Risk Transfer Deal

Updated Category News Views 191

ABN AMRO and Blackstone Collaborate on Risk Management In a notable development in the financial sector, ABN AMRO has successfully executed a significant risk transfer (SRT) transaction with funds managed by Blackstone. This strategic collaboration aims to enhance ABN AMRO's growth potential while effectively managing substantial corporate loan portfolios. The...

Continue Reading
Analyzing Williams Companies: P/E Insights and Implications

Updated Category News Views 113

Understanding the P/E Ratio of Williams Companies Currently, the stock of Williams Companies Inc. is trading at $59.89, reflecting a 0.40% increase in its price. Over the past month, the stock has surged by 15.07%, and in the past year, it has shown impressive growth of 64.19%. Such substantial performance has left long-term shareholders feeling quite optimistic. However,...

Continue Reading
Miami International Holdings Set to Launch Futures Trading Soon

Updated Category News Views 242

Miami International Holdings Plans Financial Futures Launch Miami International Holdings, Inc. (NYSE: MIAX) is gearing up to enhance its trading platform with the introduction of financial futures on MIAX Futures™. This strategic move marks a significant milestone for the company and is anticipated to offer traders new and exciting opportunities. Overview of MIAX...

Continue Reading